Pharmacists in Leonardtown, Maryland


13 Pharmacists found in Leonardtown
male pharmacist

Aaron Dailey, PHARMD


Pharmacist
40955 Merchant Lane, Leonardtown, MD 20650
301-475-7212    

female pharmacist

Abeba Hadgu


Pharmacist
40955 Merchants Ln, Leonardtown, MD 20650
301-475-7212    

female pharmacist

Debra Matthews, RPH


Pharmacist
26020 Point Lookout Rd, Leonardtown, MD 20650
301-475-8917    



male pharmacist

Mr. Dominic Aidoo, RPH


Pharmacist
25805 Point Lookout Rd, Leonardtown, MD 20650
301-481-9928     240-309-4151

male pharmacist

Joseph Rowe


Pharmacist
40955merchantlane, Leonardtown, MD 20650
301-475-7212    

female pharmacist

Kendall Korey Haney, PHARMD


Pharmacist
40955 Merchants Ln, Leonardtown, MD 20650
301-475-7212    

male pharmacist

Mark Ogunsusi, PHARMD


Pharmacist
26020 Point Lookout Rd, Leonardtown, MD 20650
301-475-8917    

female pharmacist

Prakruti Shah


Pharmacist
26020 Point Lookout Rd, Leonardtown, MD 20650
301-475-8917    

male pharmacist

Mr. Rajesh R Mehta, R.PH.


Pharmacist
25500 Point Lookout Road, Leonardtown, MD 20650
301-475-6072    

male pharmacist

Ryan Cheoun


Pharmacist
26020 Point Lookout Rd, Leonardtown, MD 20650
301-475-8917     301-997-0054

male pharmacist

Sam Theyyan Nathan, BS/PHARMACY


Pharmacist
40955 Merchants Ln, Leonardtown, MD 20650
301-475-7212    

male pharmacist

Dr. Samuel Yimamu, PHARMD


Pharmacist
26020 Point Lookout Rd, Leonardtown, MD 20650
301-475-8917     301-997-0054

female pharmacist

Sena S Ahohe, PHARMD


Pharmacist
40955 Merchants Ln, Riteaid, Leonardtown, MD 20650
301-475-7212    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.